 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Amsterdam Molecular Therapeutics (AMT) B.V.
|
-
AMT Obtains License to Amgen’s GDNF Gene to Develop Treatment for Parkinson’s Disease
(22 Sep 2008)
Amsterdam Molecular Therapeutics announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson’s disease. The combination of this gene with AMT’s proprietary adeno-associated ...
-
AMT Makes Advance in the Development of its Gene Therapy for Hemophilia B
(11 Jun 2008)
Company Accesses Technology to Prevent Immune Response
Amsterdam Molecular Therapeutics announced that it obtained a license from 'TIGET' San Raffaele Telethon Institute For Gene Therapy, Italy, to use their micro-RNA technology to prevent immune responses against gene therapy for Hemophilia B. This ...
-
AMT's Lead Product Poised to Address Major Liver Disease
(29 Jan 2008)
European Patent Office Grants Patent for Treatment of Non-alcoholic Steatotic Hepatitis
AMT announced that the European Patent Office (EPO) has granted the company an important patent for the treatment of Non-Alcoholic Steatotic Hepatitis (NASH) with its lead product AMT-11. AMT has a similar patent pending with the U.S. Patent and ...
-
Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for acute intermittent porphyria
(02 Mar 2007)
Rights from University of Navarra, Pamplona, Spain strengthen AMT's portfolio of gene therapy products
Amsterdam Molecular Therapeutics BV (AMT) announced that it has obtained exclusive worldwide rights to develop and commercialise AMT-020 as a therapeutic product from UTE CIMA, Proyecto de Biomedicina CIMA, S.L. and Digna Biotech (all parties part ...
-
Amsterdam Molecular Therapeutics BV Closes EUR22 Million Equity Financing
(06 Oct 2006)
Investment By Four Institutions Secures Growth Funding
Amsterdam Molecular Therapeutics BV (AMT) has announced the closing of its EUR22 million private placement financing (series A round) with four top tier venture capital firms, ABN AMRO Capital/Life Sciences (AACLS), Advent Venture Partners (Advent ...
-
Galapagos, Amsterdam Molecular Therapeutics, Netherlands Institute for Brain Research and Vrije Universiteit Amsterdam cooperate
(19 Sep 2005)
Galapagos, Amsterdam Molecular Therapeutics B.V. (AMT), the Netherlands Institute for Brain Research (NIBR), and the Vrije Universiteit Amsterdam (VUA) announce their collaboration to develop innovative treatments for acute spinal cord and ...
Additional information
Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam, Netherlands
Company
|
|
|
|
|
|
Top
